



# Gene-Silencing Technology and Potential Applications

Georges Saade, MD, FACC

Bellevue Medical Center
Associate Prof. Lebanese University




### INTRODUCTION

- Gene silencing is a technique that aims to reduce or eliminate the production of a protein from it's corresponding gene.
- It generally describe the "switching off" of a gene by a mechanism other than genetic modification.
- It occurs when RNA is unable to make a protein during translation.
- Gene silencing is same as gene knock down but is totally different from gene knock out.











### There are so many approaches for gene silencing

- Gene Knockout
- Gene Knockdown
- Gene silencing and degradation of gene using RNA technology
  - Antisense RNA Technology
  - RNAi Technology




## Types of Gene silencing

- Genes are regulated at either the transcriptional level or post-transcriptional level, therefore silencing can be induced either at transcriptional level or post-transcriptional level.
- There are mainly two types of gene silencing
- 1. Transcriptional gene silencing
- Post transcriptional gene silencing

Transcriptional gene silencing	Post transcriptional gene silencing			
1. Genomic Imprinting	1. Antisense RNA technology			
2. Paramutation	2. RNAi technology			
3. Transposon silencing	- mi RNA			
4. Transgene silencing	- sh RNA			
5. Position effect	- si RNA			
6. RNA-directed DNA methylation	7			








**TRANSLATION** 








**TRANSLATION** 



















# Sense mRNA Strand


















Andrew Fire and Craig Mello











#### EXOGENOUS (outside origin)



#### **ENDOGENOUS**


(inside origin)























# SO WHAT???










# SO WHAT???




MANY TREATMENTS
BLOCK THIS






# SO WHAT???



MANY TREATMENTS
BLOCK THIS



















RNA in the CONTROL of GENE EXPRESSION - a

Nobel story

The gene is transcribed into a specific RNA species, mRNA

The gene is transcribed into a specific RNA species, mRNA

The genetic code M. Nirenberg and G. Whereau Nobel Brita in



The double-helix of DNA identified as the genetic material F.Crick, J. Watson and M. Wilkins; Nobel Prize in Physiology or Medicine (1962)

The split gene
P. Sharp and R. Roberts;
Nobel Prize (1993)

RNA can act as a catalyst S. Altman and T. Cech; Nobel Prize in Chemistry (1989)








#### mirna functions in Mammals


Up to now about 800 miRNA have been discovered in humans, and probably a vast % of human genes are controlled by miRNA activity

- Cell proliferation
- Cell death
- Cell differentiation
- Embryonic development
- Cancer
- Viral infections













miRNAs are involved in all aspects of cardiovascular function




Figure 1. Breakthrough discoveries in miRNA biology. Time line indicating seminal discoveries in miRNA biology with a special focus on the cardiovascular field.

Circ Res. 2011;108:219-234





Figure 2. MicroRNAs (MiRNAs) in postin farction repair.

Giacca, M, et al. 2015. J Mol Cell Cardiol 89, 68 Giacca, M 2015. Mol Ther 23, 984 Aguirre, A, et al. 2014. Cell Stem Cell 15, 589 Zacchigna, S, et al. 2014. Circ Res 114, 1827






# miR-92a regulates angiogenesis







#### Antagomir-92 improves the recovery after ischemia










# Inhibition of MicroRNA-92a Protects Against Ischemia/Reperfusion Injury in a Large-Animal Model

Animals: male pigs, German landrace, body weight: 20-25kg

- Induction of acute myocardial infarction (AMI) by occlusion of the left anterior descending (LAD) using a PTCA balloon
- After 55 minutes of ischemia: Infusion of LNA-92a
   (5 mg/kg heart weight; 0.03mg/kg body weight; 0.75mg/pig)
- Reperfusion after 60 minutes of ischemia
- 4) Harvest 72 hours after AMI




Rabea Hinkel & Christian Kupatt, Munich



In partnership with:



# Inhibition of MicroRNA-92a in pigs after Ischemia/Reperfusion Injury











# LNA-92a Improve cardiac function








# LNA-92a increases capillary dencity











# Regulation of miRNAs during cardiovascular aging










Figure 2 | miR-34a reduction inhibits age-related and myocardial infarction-induced cardiomyocyte cell death and cardiac function.





Groups	miRNAs	Sources	RNA Isolation	Expression	miRNA Detection	Potential value	Reference
AMI	miR-208	Rat	Plasma	Up-regulation	Microarray and qRT-PCR	Diagnostic biomarker	[23]
	miR-208a	Rat, Human	Plasma	Up-regulation	Microarray and qRT-PCR	Diagnostic biomarker	[6]
	miR-208b	Human	Plasma	Up-regulation	qRT-PCR	Diagnostic biomarker	[24,30]
	miR-499	Human	Plasma	Up-regulation	qRT-PCR	Diagnostic biomarker	[24,25,30]
	miR-1	Human	Plasma	Up-regulation	qRT-PCR	Diagnostic biomarker	[30,63]
	miR-133	Human	Plasma	Up-regulation	qRT-PCR	Diagnostic biomarker	[60]
	miR-30a	Human	Plasma	Up-regulation	qRT-PCR	Diagnostic biomarker	[61]
	miR-150	Human	Plasma	Down-regulation	qRT-PCR	Prognostic biomarker	[62]
	let-7b	Human	Plasma	Down-regulation	qRT-PCR	Diagnostic biomarker	[61]
	miR-126	Human	Plasma	Down-regulation	qRT-PCR	Diagnostic biomarker	[63]
HF	miR-423, miR-18b	Human	Plasma	Up-regulation	Microarray and qRT-PCR	Diagnostic biomarker	[9]
	miR-499	Human	Plasma	Up-regulation	qRT-PCR	Diagnostic biomarker	[24]
	miR-103, miR-142	Human	Plasma	Down-regulation	Microarray	Diagnostic biomarker	[42]
	miR-320a, miR-22	Human	Serum	Up-regulation	qRT-PCR	Prognostic biomarker	[43]
	miR-16,	Rat	Plasma	Up-regulation	Microarray and	Disease progression and	[45]
	miR-20b				qRT-PCR	therapeutic efficacy	
	miR-26b	Human	Plasma, Serum	Up-regulation	qRT-PCR	Diagnostic and prognostic biomarker	[47]
HTN	miR-296, miR-133b, miR-625, miR-1236	Human	Plasma	Down-regulation	Microarray and qRT-PCR	Pathogenesis of essential hypertension	[10]
	let-7e, Hcmv-miR-UL112, miR-605,miR-623, miR-516b	Human	Plasma	Up-regulation	Microarray and qRT-PCR	Pathogenesis of essential hypertension	[10]
	miR-132, miR-212	Human, Rat	Plasma	Up-regulation	Microarray and qRT-PCR	Mechanisms of essential hypertension	1511
Stroke	miR-145	Human	Blood	Up-regulation	qRT-PCR	Diagnostic biomarker	1531
	miR-21	Human	Plasma	Up-regulation	qRT-PCR	Diagnostic biomarker	1541
	miR-221	Human	Plasma	Down-regulation	qRT-PCR	Diagnostic biomarker	1541
	miR-210	Human	Blood	Down-regulation	qRT-PCR	Diagnostic and prognostic biomarker	[55]
	miR-290	Rat	Blood	Up-regulation	Microarray and qRT-PCR	Diagnostic biomarker and mechanisms of stroke	[56]
	let-7i	Rat	Blood	Down-regulation	Microarray and qRT-PCR	Diagnostic biomarker and mechanisms of stroke	[56]
	miR-298	Rat	Blood	Up-regulation	Microarray	Diagnostic biomarker	[57]
	miR-155	Rat	Blood	Down-regulation	Microarray	Diagnostic biomarker	[57]
	miR-30a,	Human	Plasma	Down-regulation	qRT-PCR	Diagnostic biomarker	[60]
	miR-126						

Common circulating miRNAs in cardiovascular disease


Heart, Lung and Circulation (2014) 23, 503-510

Note: AMI: Acute myocardial Infarction, HTN: Hypertension, HF: Heart failure, qRT-PCR: quantitative reverse transcription-polymerase chain reaction





#### From: miRNAS in cardiovascular diseases: potential biomarkers, therapeutic targets and challenges



miRNAs as therapeutic targets for cardiovascular diseases. Increased expression (arrow head) or decreased expression (barhead) provides beneficial or protective effects in the treatment of CVD.

# Therapeutic Manipulation of miRNAs

miRNAs in Heart Failure: miR-133 is highly abundant in cardiomyocytes, but is reduced in animal models of hypertrophy and in patients with hypertrophic cardiomyopathy miRNAs in Neointima Formation and Atherosclerosis: In addition to its profibrotic role, miR-21 enhances neointimal growth through pro-proliferative and antiapoptotic effects onvascular smooth muscle cells (SMCs). Inhibition of miR-21 reduces instent restenosis in animals

Barwari et al. JACC VOL. 68, NO. 23, 2016



miRNAs in Lipid Metabolism: Systemic inhibition of miR-148a caused a significant reduction in plasma lowdensity lipoprotein cholesterol, but also increased highdensity lipoprotein cholesterol levels. Long-term side effects of miR-122 and miR-33 inhibition, combined with the advent of novel therapeutic options for dyslipidemia, may limit the clinical use of miRNAs to modulate lipid metabolism.

Barwari et al. JACC VOL. 68, NO. 23, 2016







Figure 1. Biogenesis of circulating miRNAs. miRNAs are transcribed in the nucleus as pri-miRNAs with 5'-caps and 3'-polyA tails. Drosha removes the cap and polyA tail to generate pre- miRNAs, which are exported from the nucleus via Exportin 5. In the cytoplasm Dicer processes the pre-miRNA to mature miRNAs. Pre-miRNA and mature miRNA can (a) bind to RNA-binding proteins to be directly excreted from the cell, (b) packaged into microvesicles or (c) packed into exosomes and multi-vesicular bodies where the exosomes are then released. Pre-miRNA and mature miRNAs are taken into the bloodstream by endocytosis, binding to receptors or via membrane fusion.



#### miRNAS in cardiovascular diseases: potential biomarkers, therapeutic targets and challenges



miRNAs associated with the diagnosis and prognosis of heart failure, acute myocardial infarction and arrhythmia. miRNAs in blue boxes are associated with a single pathology, while those in yellow boxes with multiple pathologies.





## Conclusion

- 1. Caution needs to be exercised to avoid moving toward clinical evaluation too quickly..
- 2. Targeting individual miRNAs therefore requires meticulous evaluation of systemic effects
- 3. A careful approach in advancing miRNA therapies may slow progression toward clinical application, but may spare miRNA therapeutics a setback similar to gene therapy.
- 4. The great potential of miRNAs justifies the exercise of apprehension before large-scale clinical studies for CVD.



